Sandbox: m: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
Line 1: Line 1:
{| style="border: 0px; font-size: 90%; margin: 3px; width: 600px"
{| style="border: 0px; font-size: 90%; margin: 3px; width: 500px"
|valign=top|
|valign=top|
|+  '''Cardiac Myxoma'''
|+  '''Cardiac Myxoma'''
Line 9: Line 9:


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''General aspects'''|| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''General aspects'''|| style="padding: 5px 5px; background: #F5F5F5;" |
:* Older age at the time of diagnosis is associated with a worse prognosis.
:*Isolated cells with irregular cellular borders, mild or no atypia, no mitosis


|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Genetics'''|| style="padding: 5px 5px; background: #F5F5F5;"|
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Genetics'''|| style="padding: 5px 5px; background: #F5F5F5;"|
:* Males are associated with a worse prognosis when compared to females.
:*[[PRKAR1A]] gene plays an important role in cardiac development and myxomagenesis
|-
|-




| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Gross Pathology'''|| style="padding: 5px 5px; background: #F5F5F5;"|
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Gross Pathology'''|| style="padding: 5px 5px; background: #F5F5F5;"|
:* Patient's poor [[performance status]] is associated with a worse prognosis.
:*Smooth, lobulated mass can be friable or gelatinous
|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Micropathology'''|| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Micropathology'''|| style="padding: 5px 5px; background: #F5F5F5;" |
:*Binet stages B and C or Rai stages 2-4 are associated with a worse prognosis.
:*Inflammatory infiltrate with hemosiderin, calcifications and extramedullary hemopoyesis


|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Inmunohistochemistry'''|| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Inmunohistochemistry'''|| style="padding: 5px 5px; background: #F5F5F5;" |
:*A rapid [[lymphocyte]] doubling time is associated with a worse prognosis.
:*Vimentin, endothelial and neural markers


|}
{| style="cellpadding=0; cellspacing= 0; width: 150px;"align=left";
|-
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 20%" align=center |'''Myxoma'''
|-
|style="font-size: 100; padding: 0 5px; background: #FFFFFF" align=center |'''General aspects'''
Isolated cells with irregular cellular borders, mild or no atypia, no mitosis
|-
|style="font-size: 100; padding: 0 5px; background: #FFFFFF" align=center |'''Gross pathology'''
Smooth, lobulated mass can be friable or gelatinous
|-
|style="font-size: 100; padding: 0 5px; background: #FFFFFF" align=center |'''Vascular pattern'''
Perivascular structures
|-
|style="font-size: 100; padding: 0 5px; background: #FFFFFF" align=center |'''Inmunohistochemistry'''
Vimentin, endothelial and neural markers
|-
|style="font-size: 100; padding: 0 5px; background: #FFFFFF" align=center |'''Others'''
Inflammatory infiltrate with hemosiderin,calcifications and extramedullary hemopoyesis.
|-


|}
|}

Latest revision as of 15:13, 24 November 2015

Cardiac Myxoma
Features Description
General aspects
  • Isolated cells with irregular cellular borders, mild or no atypia, no mitosis
Genetics
  • PRKAR1A gene plays an important role in cardiac development and myxomagenesis
Gross Pathology
  • Smooth, lobulated mass can be friable or gelatinous
Micropathology
  • Inflammatory infiltrate with hemosiderin, calcifications and extramedullary hemopoyesis
Inmunohistochemistry
  • Vimentin, endothelial and neural markers